NCT02841241

Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia

Esmolol to Control Adrenergic Storm in Septic Shock - Roll-in

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Intermountain Health Care, Inc. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single arm, "roll-in" study of esmolol infusion for patients with septic shock with persistent tachycardia after adequate intravenous volume expansion. The study will evaluate the adequacy and efficiency of study protocols for the anticipated, main ECASSS study, which will have a separate entry in clinicaltrials.gov.

Detailed description

PRIMARY OBJECTIVE: To evaluate the adequacy and efficiency of study protocols for the anticipated, randomized, controlled ECASSS study. The primary clinical outcome is organ-failure free days at 28 days, with multiple secondary outcomes, including those relevant to function of and compliance with the study protocols.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DRUG	Esmolol	Esmolol infusion

Timeline

• Start date: 2016-04-01
• Primary completion: 2017-03-01
• Completion: 2017-03-01
• First posted: 2016-07-22
• Last updated: 2019-01-09
• Results posted: 2019-01-09

Locations

1 site across 1 country: United States